APGE news

Apogee Therapeutics agreed to be acquired by AbbVie for approximately $10.9 billion while also reporting Q2 2026 financial results and positive Phase 2 data for its atopic dermatitis candidate, which may bolster the acquisition price.

AbbVie announced a definitive agreement to acquire Apogee Therapeutics for $135.11 per share, totaling approximately $10.9 billion in equity value. The acquisition adds a clinical-stage immunology pipeline focused on inflammatory and immunological diseases including atopic dermatitis and asthma, str…

Apogee Therapeutics announced a strategic financing collaboration with Blackstone Life Sciences providing up to $1.3 billion in non-dilutive capital, including $800 million in synthetic royalty and $500 million in senior debt, to fund Phase 3 development and commercialization of zumilokibart for ato…

Apogee announced positive 16-week Part B induction dose optimization results from its Phase 2 APEX trial of zumilokibart, with 65.9% of mid-dose patients achieving EASI-75 endpoints. The company plans to advance the mid-dose into Phase 3 trials in 2H 2026 and secured strategic financing from Blackst…